Moderna’s personalized mRNA cancer vaccine has shown success in a late-stage clinical trial, potentially transforming how doctors treat the deadliest form of skin cancer.
The vaccine, developed in combination with Merck’s immunotherapy Keytruda, met its primary goals in the Phase 3 INTerpath-001 study involving more than 1,100 patients with higher-risk or advanced melanoma.
Patients enrolled in the trial had detectable cancer that was completely removed through surgery before receiving the experimental treatment combination.
The study met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in patients with completely resected stage IIB-IV melanoma skin cancer.
Interim results showed the vaccine and drug combination appeared to extend the time before cancer returned in high-risk patients, though the companies did not disclose exactly how long that extension was.
The mRNA-based shot relies on the same foundational technology used to develop COVID-19 vaccines, making it the first mRNA-based cancer treatment to demonstrate success in a late-stage trial.
Each dose of the vaccine is built from a patient’s own tumor tissue, which carries its own unique genetic sequence, allowing the treatment to be fully personalized for each individual.
The vaccine specifically targets abnormal proteins called neoantigens that appear on the surface of cancer cells, training the immune system to identify and attack them.
Markets responded dramatically to the announcement, with Merck shares climbing more than 12% and Moderna’s stock soaring approximately 177% on the day of the news.
Despite the excitement, analysts and investors are urging caution, as the complete Phase 3 dataset has not yet been publicly released for full scientific review.
Following an intraday gain approaching 150% for Moderna (MRNA), much of the optimism was immediately priced into the stock, raising concerns about chasing such a large single-day biotech move without complete trial data.
If the full results confirm the interim findings, they could signal what some researchers are calling a potentially seismic breakthrough not only for melanoma but for the broader treatment of other cancer types as well.
The broader political environment adds another layer of uncertainty for mRNA technology, with Health Secretary Robert F. Kennedy Jr. having repeatedly criticized mRNA research and development.
Kennedy slashed $500 million in contracts last year for mRNA vaccine research and development, raising questions about the long-term federal support for this class of treatments under the current administration.
